Clinical interventions in aging · 2006 · Commentary · PMID 18046908
Explore the library
Limited human evidenceGHRH (1–29) analog
Sermorelin
Sermorelin is an analog of the first 29 amino acids of growth hormone-releasing hormone. Historical Geref products were approved and later discontinued; current compounded products require separate regulatory interpretation.
Also indexed as: GRF 1-29 · Geref
A clear starting point
Sermorelin is an analog of the first 29 amino acids of growth hormone-releasing hormone. Historical Geref products were approved and later discontinued; current compounded products require separate regulatory interpretation.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
GHRH / GH–IGF-1
Sermorelin is an analog of the first 29 amino acids of growth hormone-releasing hormone. Historical Geref products were approved and later discontinued; current compounded products require separate regulatory interpretation.
- Targets & processes
- GHRH / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Pituitary GH response and historical pediatric GH-deficiency research.
What this does not establish
The linked article is a commentary, not a randomized anti-aging trial. Historical Geref approval and discontinuation do not make current compounded formulations FDA-approved.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Potential endocrine effects, glucose changes, fluid retention and hypersensitivity require clinical assessment. Long-term anti-aging use lacks adequate evidence.
Contraindications & cautions
Not an exhaustive contraindication review. Potential endocrine effects, glucose changes, fluid retention and hypersensitivity require clinical assessment. Long-term anti-aging use lacks adequate evidence.
Medication & supplement interactions
Interaction information is incomplete. Potential endocrine effects, glucose changes, fluid retention and hypersensitivity require clinical assessment. Long-term anti-aging use lacks adequate evidence.
Regulatory status · United States
Historical FDA product · discontinued. Geref was historically FDA-approved and later discontinued; FDA determined withdrawal from sale was not for safety or effectiveness reasons. Current compounded preparations are not FDA-approved finished drugs.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.